Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma

Therapeutic Drug Monitoring

Volumn 19, Issue 6, 1997, Pages 632-636

  El Yazigi, Adnan ^a,b   Berry, John ^b   Ezzat, Adnan ^b   Wahab, Fida Abdel ^a  

^a Dept of Biol and Medical Research ^*  (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Doxorubicin; Multiple drug resistance modulation; Non Hodgkin's lymphoma; Pharmacokinetics; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; DOUBLE-BLIND METHOD; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 0031471047     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199712000-00005     Document Type: Article

References (27)

1. Chabner BA, Clendeninn NJ, Curt GA. Introduction to the symposium on cellular resistance to anticancer drugs. Cancer Treat Rep 1983;67:855-7.
2. Fojo A, Akiyama SI, Gottesman MM, Pastan I. Reduced drug accumulation in multiple drug resistant human KB carcinoma cell lines. Cancer Res 1985;45:3002-7.
3. Inaba M, Kobayashi H, Sakurai Y, Johnson RK. Active efflux of daunorubicin and Adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 1979;39:2200-3.
4. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and Adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982;42:4730-3.
5. Chauffert B, Martin M, Hamman A, Michel MF, Martin F. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cells in vitro and in vivo. Cancer Res 1986;46:825-30.
6. Ramu A, Fuks Z, Gatt S, Glaubiger D. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexilene maleate. Cancer Res 1984;44:144-8.
7. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL. Identification of the multidrug resistance related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987;262:7884-8.
8. Chatterjee M, Harris AL. Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and-4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein. Br J Cancer 1990;62:712-7.
9. Ramu A, Fuks Z, Gatt S, Glaubiger D. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 1984;44:4392-5.
10. Millward MJ, Cantwell BMJ, Lien EA, Carmichael J, Harris AL. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992;28A:805-10.
11. Stuart NSA, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J. High-dose tamoxifen as an enhancer of etoposide cytoloxicity, clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 1992;66:833-9.
12. Kerr DJ, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239-42.
13. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12:835-42.
14. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effect of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994;74:834-41.
15. El-Yazigi A, Al-Saleh I. Rapid analysis of doxorubicin in plasma by radial compression liquid chromatography. J Pharm Sci 1985; 74:1225-7.
16. Gibaldi M, Perrier D. Pharmacokinetics. New York, NY: Marcel Dekker, 1975;45-96.
17. Raoul JL, Heresbach D, Bretagne JF, et al. Chemoembolization of hepatocellular carcinomas. Cancer 1992;70:585-90.
18. Eksborg S, Nordenstrom BEW, Beving H. Electrochemical treatment of cancer, III: Plasma pharmacokinetics of Adriamycin after intraneoplastic administration. Am J Clin Oncol 1990;13:164-6.
19. Pommerenke E, Mattern J, Volm M. Modulation of doxorubicintoxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo. J Cancer Res Clin Oncol 1994;120:422-6.
20. Kang Y, Perry RR. Modulatory effects of tamoxifen and recombinant human a-interferon on doxorubicin resistance. Cancer Res 1993;53:3040-5.
21. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res 1994;54:441-7.
22. Millward MJ, Lien EA, Robinson A, Cantwell BM. High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology 1994;51:79-83.
23. Miller AA, Schmidt CG. Clinical pharmacology and toxicity of 4′-O-tetrahydropyranyladriamycin. Cancer Res 1987;47:1461-5.
24. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin [review]. Clin Pharmacokinet 1988;15:15-31.
25. Preiss R, Sohr R, Kittelmann B, Muller E, Haase D. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites. Int J Clin Pharmacol Ther Toxicol 1989;27:156-64.
26. Preiss R, Matthias M, Sohr R, Brockmann B, Huller H. Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. J Cancer Res Clin Oncol 1987;113:593-8.
27. Johnson PJ, Kalayci C, Dobbs N, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 1991;13:120-7.